Coronado plans to use the proceeds to fund R&D, clinical trials and manufacture of supply as well as other corporate purposes...OxiGene Inc., of South San Francisco, entered agreements with institutional investors for a private placement of $5 million of zero coupon convertible preferred stock, convertible into approximately 1.38 million shares of common stock at a price of $3.63 apiece, and two series of warrants that may be exercised for up to approximately 2.76 million additional shares of

Exelixis Inc., of South San Francisco, presented additional information about the mechanism of action of cabozantinib with respect to activity against prostate cancer tumors metastasized to bone...MEI Pharma Inc., of San Diego, presented data showing the ability of its mitochondrial inhibitor drug candidate, ME-344, to decrease tumor burden and delay recurrence in a preclinical in vivo model of recurrent epithelial ovarian cancer

newly commercial orphan drug developer Hyperion Therapeutics Inc., of South San Francisco...and London-based GW Pharma plc, which is seeking a Nasdaq listing and a capital raise. (See BioWorld Today, March 11, 2013, March 12, 2013, and March 20, 2013.) In other financings news...Net proceeds are expected to support clinical trial costs and acquisition of manufacturing equipment, leasehold improvements and general corporate purposes

The company plans to use proceeds from the offering to complete clinical development of Ravicti in hepatic encephalopathy (HE) and to fund post-approval studies in UCD...Hyperion gained rights to Ravicti from Ucyclyd Pharma Inc., a subsidiary of Scottsdale, Ariz.-based Medicis Pharmaceutical Corp...at the same unit price.

Acceleron Pharma Inc., of Cambridge, Mass., said it started a Phase II study testing dalantercept (ACE-041), an angiogenesis inhibitor designed to target the activin receptor-like kinase pathway, in combination with Inlyta (axitinib, Pfizer Inc.), a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma...Portola Pharmaceuticals Inc., of South San Francisco, inked a clinical collaboration with Janssen Pharmaceuticals Inc., a unit of

Clinical Cancer Research included a paper that suggested the compound, ENMD-2076, acts potently against breast cancer cell lines that lack expression of the estrogen and progesterone receptors, while also lacking HER2 amplification, i.e., TNBC...KaloBios Pharmaceuticals Inc., of South San Francisco, set the terms on its previously disclosed initial public offering

Cerulean Pharma Inc., of Cambridge, Mass., said CRLX101 achieved the predefined gating criterion for advancement into the second stage of a Phase II trial in advanced ovarian cancer...That allows Lorus to initiate a biomarker clinical investigation to further explore the effects of the drug at relevant doses determined in the trial...The complete clinical study report for the interim analysis would be supplied to the FDA during the review within 60 days of the resubmission

Cerulean Pharma Inc., of Cambridge, Mass., said it dosed the first patient in a Phase II study of lead candidate CRLX101 in advanced gastric cancer...Onyx Pharmaceuticals Inc., of South San Francisco, and Bayer AG, of Leverkusen, Germany, reported that a Phase III trial of Nexavar (sorafenib) in locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer met its primary endpoint of a statistically significant improvement of progression-free survival

CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7...OxiGene Inc., of South San Francisco, said data from a Phase II trial of Zybrestat (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), were presented at the annual meeting of the American Academy of Ophthalmology

The FDA granted Xtandi (enzalutamide, Astellas Pharma Inc. and Medivation Inc.) approval in September for metastatic castration-resistant prostate cancer patients who have previously received docetaxel. (See BioWorld Today, Sept. 4, 2012.) Dendreon said it is looking for a European marketing partner, rather than just a manufacturing partner...Onyx Pharmaceuticals Inc., of South San Francisco, reported net sales of $18.6 million for newly launched cancer drug Kyprolis (carfilzomib), while sales of

Cytokinetics Inc., of South San Francisco, said it opened its Phase IIb BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) testing tirasemtiv, formerly CK-2017357, in patients with amyotrophic lateral sclerosis (ALS...TransTech Pharma Inc., of High Point, N.C., said data from a 399-patient study testing TTP488, a small-molecule drug targeting the receptor for advanced glycation endproducts, demonstrated evidence of slowing cognitive decline

The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.

AlphaCore Pharma Inc., of Ann Arbor, Mich., said its Phase I trial met the primary endpoint by demonstrating the safety and tolerability of ACP-501 (recombinant human LCAT...The positive clinical effects of the twice-daily dose of the drug relative to placebo were observed in a variety of standard psoriasis assessment parameters, with the responses accumulating over the 24 weeks...Seattle Genetics Inc., of Bothell, Wash., said it will receive undisclosed milestone payments under its antibody-drug

Horizon Pharma Inc., of Deerfield, Ill., priced an underwritten public offering of 21.42 million units, with each unit consisting of one share of its common stock and a warrant to purchase a half share of its common stock...Sunesis Pharmaceuticals Inc., of South San Francisco, executed two previously disclosed financings...Royalty Pharma has invested $25 million under its royalty arrangement with Sunesis, and, in a separate transaction, a syndicate of lenders funded the second tranche of $15 million

Horizon Pharma Inc., of Deerfield, Ill., filed an S3 shelf registration with the SEC for a public offering not to exceed $175 million...The specialty pharma raised $49.5 million a year ago in its initial public offering...Hyperion Therapeutics Inc., of South San Francisco, completed its initial public offering of 5 million shares of common stock at $10 each for proceeds of $50 million

BHR Pharma LLC, of Phoenix, said it reached its SyNAPSe clinical trial enrollment midpoint of 590 patients...Onyx Pharmaceuticals Inc., of South San Francisco, said results from the 003-A1 single-arm Phase IIb trial evaluating Kyprolis (carfilzomib) for injection in patients with advanced multiple myeloma who had received a median of five prior anti-myeloma regimens were published in Blood

Berg Pharma LLC, of Boston, began a Phase I trial of compound 31543 for chemotherapy-induced alopecia...Cerulean Pharma Inc., of Cambridge, Mass., said it dosed the first patient in a Phase II study testing CRLX101 in platinum-resistant ovarian cancer...Onyx Pharmaceuticals Inc., of South San Francisco, Bayer HealthCare Pharmaceuticals Inc., of Wayne, N.J., and Astellas Pharma Inc., of Tokyo, said a Phase III trial of Tarceva (erlotinib) with Nexavar (sorafenib) failed to improve overall survival for

Cerulean Pharma Inc., of Cambridge, Mass., completed enrollment in a Phase II trial of CRLX101, in non-small-cell lung cancer (NSCLC) and dosed its first patient in a Phase Ib/IIa trial of the same product in combination with Avastin (bevacizumab, Roche AG) in metastatic renal cell carcinoma (mRCC...Onyx Pharmaceuticals Inc., of South San Francisco, began enrollment in its ENDEAVOR Phase III trial of Kyprolis (carfilzomib) in combination with dexamethasone vs. Velcade (bortexomib, Millennium: The

Hyperion Therapeutics Inc., of South San Francisco, said a 178-patient Phase II study of glycerol phenylbutyrate, a pre-prodrug of phenylacetic acid, in episodic hepatic encephalopathy (HE) met its primary endpoint...Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, completed enrollment of 1,680 patients in the Phase III PREVAIL study of enzalutamide for advanced prostate cancer